Immunome, Inc. - Common Stock (NQ:IMNM)

21.17 +0.27 (+1.29%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Immunome, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors

September 30, 2026

From Immunome, Inc.

Via Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 08, 2026

From Immunome, Inc.

Via Business Wire

Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 02, 2026

From Immunome, Inc.

Via Business Wire

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026

From Immunome, Inc.

Via Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 06, 2026

From Immunome, Inc.

Via Business Wire

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

July 20, 2026

From Immunome, Inc.

Via Business Wire

What This Immunome Sale Means a Day Before a Big FDA Milestone ↗

July 12, 2026

Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026.

Via The Motley Fool

Topics Regulatory Compliance

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

July 08, 2026

From Immunome, Inc.

Via Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 07, 2026

From Immunome, Inc.

Via Business Wire

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

June 11, 2026

From Immunome, Inc.

Via Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 04, 2026

From Immunome, Inc.

Via Business Wire

Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting

May 30, 2026

From Immunome, Inc.

Via Business Wire

Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 27, 2026

From Immunome, Inc.

Via Business Wire

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

From Immunome, Inc.

Via Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 05, 2026

From Immunome, Inc.

Via Business Wire

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

April 29, 2026

From Immunome, Inc.

Via Business Wire

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

April 21, 2026

From Immunome, Inc.

Via Business Wire

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More ↗

April 04, 2026

This biotech innovator in antibody therapeutics reported a notable insider sale amid a year of dramatic share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 02, 2026

From Immunome, Inc.

Via Business Wire

ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗

March 21, 2026

This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway.

Via The Motley Fool

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 05, 2026

From Immunome, Inc.

Via Business Wire

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗

March 04, 2026

Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.

Via The Motley Fool

Topics Regulatory Compliance

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

March 03, 2026

From Immunome, Inc.

Via Business Wire

Immunome to Present at Upcoming Investor Conferences

February 23, 2026

From Immunome, Inc.

Via Business Wire

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.

Via The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗

February 22, 2026

This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.

Via The Motley Fool

Topics Regulatory Compliance

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

February 22, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗

February 22, 2026

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗

February 22, 2026

Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 05, 2026

From Immunome, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.